Traws Pharma, Inc. announced positive topline results on March 3, 2025, from ferret studies evaluating tivoxavir marboxil as a single-dose treatment for H5N1 bird flu. Ferrets are an accepted animal model for human influenza, and these data are consistent with previous murine model results reported in December 2024.
The studies assessed the efficacy of a single dose of tivoxavir marboxil against bird flu isolated from a Texas dairy worker. Results showed suppression of disease and a reduced viral burden in the lungs of infected ferrets.
In a lethal challenge in ferrets, tivoxavir marboxil increased the proportion of surviving animals and lowered the viral burden in both lungs and nasal tissues. The company plans to approach the FDA to discuss an accelerated approval pathway under the “Animal Rule” following upcoming non-human primate data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.